Hydrocodone
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Hydrocodone is a semi-synthetic opioid of the morphinan class. It is derived from codeine and occupies a mid-potency position alongside oral morphine. Hydrocodone is a full agonist at μ-opioid receptors,[1] producing its effects by suppressing pain signaling and activating reward pathways in the brain.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, oxycodone, heroin +5 moremorphine, oxycodone, heroin, fentanyl, methadone, hydromorphone, codeine, tramadol show less
First synthesized by Carl Mannich and Helene Löwenheim in Germany in 1920, hydrocodone was approved for clinical use in the United States in 1943. It became the most-prescribed drug in the country by 2011,[2] with the United States consuming approximately 99% of the global supply,[3] and its widespread availability played a central role in the American opioid crisis. All hydrocodone products were rescheduled to Schedule II in 2014, imposing the strictest federal prescribing controls.
Subjective effects include analgesia, euphoria, sedation, and anxiolysis. The experience is one of warm, heavy calm — physical pain and emotional distress recede into a diffuse contentment in which mental activity slows and the body feels weighted. Nausea, constipation, cognitive impairment, and respiratory slowing are characteristic unsought effects.
Hydrocodone produces rapid physical dependence and carries high acute toxicity through dose-dependent respiratory depression. Tolerance to analgesia develops faster than tolerance to respiratory depression, meaning dose escalation progressively narrows the margin between effective and lethal doses — a margin further compressed by co-ingestion of alcohol, benzodiazepines, or other depressants. Decades of clinical use and epidemiological data provide a robust evidence base, though individual response varies substantially with genetic metabolizer status.[4]
History[edit]
Discovery
Hydrocodone was first synthesized in 1920 by Carl Mannich and Helene Löwenheim in Germany, as part of investigations into a class of reactions that would later bear Mannich's name.[5] The compound was produced by partial synthesis from codeine — reducing the 6-keto group and hydrogenating the 7,8-double bond — and patented in 1923. It represented one of several early 20th-century efforts to develop opioid analgesics with improved profiles relative to morphine.
Clinical adoption and the opioid crisis
Hydrocodone received FDA approval on March 23, 1943, initially for cough suppression and pain management.[5] For decades it was marketed almost exclusively in combination with acetaminophen (as Vicodin and Norco) or ibuprofen. Because combination products were classified as Schedule III rather than Schedule II, prescribing restrictions were minimal — telephone prescriptions, refills, and large supply quantities were permitted. By 2011, hydrocodone combination products had become the most-prescribed drug class in the United States, with 136.7 million annual prescriptions,[2] and the country accounted for approximately 99% of global consumption.[3]
Rescheduling and modern era
Escalating misuse and overdose mortality — opioid analgesic poisoning deaths exceeded heroin and cocaine deaths combined by 2002[6] — drove the DEA to reschedule all hydrocodone combination products from Schedule III to Schedule II on October 6, 2014.[7] The reclassification had measurable effects: 78.8% of surveyed physicians modified their prescribing behavior,[8] and hydrocodone use declined significantly across multiple patient populations.[9][10] Contemporary research focuses on pharmacogenomics-guided prescribing[11][12] and non-opioid analgesic alternatives benchmarked against hydrocodone.[13]
The name "hydrocodone" derives from its chemical relationship to codeine: "hydro-" reflects the hydrogenation of codeine's 7,8-double bond, and "-codone" preserves the parent compound's identity. In American drug culture, hydrocodone became synonymous with its most recognizable brand name, Vicodin — a cultural fixture referenced widely in television, music, and film. The television series House M.D. (2004–2012) made Vicodin a visual shorthand for functional opioid dependence.
Chemistry[edit]
Structural class
Hydrocodone belongs to the morphinan chemical class, sharing the pentacyclic (five-ring) scaffold characteristic of the morphine alkaloid family. It is classified as a substituted morphinan — a 4,5α-epoxymorphinan-6-one bearing a methoxy group at position 3 and an N-methyl substituent. This places it in the same chemical lineage as codeine, from which it is semi-synthetically derived, and hydromorphone, to which it is metabolically converted.
Molecular identity
| Molecular formula | C₁₈H₂₁NO₃ |
| Molecular weight | 299.4 g/mol |
The morphinan scaffold comprises a phenanthrene core (rings A, B, C) fused to a piperidine ring (D) and an oxygen-bridged furan ring (E). Key functional groups include a 3-methoxy ether (distinguishing hydrocodone from hydromorphone), a 6-ketone (distinguishing it from dihydrocodeine), and an N-methyl tertiary amine. The saturated C-ring differentiates hydrocodone from codeine, which retains a 7,8-double bond.
Structure-activity relationships
The methoxy group at C-3 is the defining structural distinction between hydrocodone and hydromorphone. Enzymatic removal of this single methyl group yields the free phenol of hydromorphone, which binds the μ-opioid roughly 33 times more strongly than the parent compound.[1] This steep structure-activity gradient — one methyl group producing a dramatic shift in receptor affinity — illustrates the sensitivity of the morphinan binding pocket to small structural modifications.
Stereochemistry
Hydrocodone possesses four contiguous stereocenters, yielding the (−)-enantiomer as the sole commercially manufactured and pharmacologically active form. The absolute configuration is consistent with the naturally occurring (−)-morphine series, from which the semi-synthetic pathway preserves stereochemical integrity. The (+)-enantiomer has not been characterized pharmacologically.
Pharmacology[edit]
Mechanism of action
Hydrocodone is a full agonist at the μ-opioid in both the central and peripheral nervous system. Receptor activation triggers an inhibitory signaling cascade: neurons become less excitable, reducing pain signal transmission throughout the spinal cord and brain.[14]
The downstream consequences of this activation include suppression of pain at the spinal cord and brainstem, cough reflex suppression, increased dopamine release in reward circuits (producing euphoria), dose-dependent respiratory depression, and slowed gut motility.
A critical distinction separates hydrocodone from most opioids: the body converts a portion of each dose into hydromorphone, a metabolite that binds the μ-opioid receptor roughly 33 times more strongly than hydrocodone itself.[1] Clinical data confirm that plasma hydromorphone concentration — not hydrocodone — predicts pain suppression, establishing the metabolite as a principal driver of therapeutic effect.[4]
This conversion depends on a liver enzyme whose activity varies genetically across the population. People who metabolize poorly through this pathway experience less analgesia and euphoria from hydrocodone, while ultra-rapid metabolizers may experience disproportionately strong effects at standard doses.[15]
Pharmacokinetics
Hydrocodone is taken exclusively by the oral route. After absorption, it undergoes extensive processing in the liver through two primary pathways[16][17][18]: the major pathway produces norhydrocodone (largely inactive), while the minor pathway yields hydromorphone (highly active at the μ-opioid receptor). Parent hydrocodone accounts for approximately 39% of urinary output, norhydrocodone approximately 49%, and hydromorphone approximately 12%.[18]
For extended-release formulations, peak blood levels occur at approximately 18 hours, with an half-life of 8.4–8.5 hours.[17] Immediate-release formulations reach effect within 10–60 minutes.citation needed
Hydrocodone is equianalgesic with oral morphine at a 1:1 ratio.[19] Drugs that inhibit the CYP2D6 enzyme — including paroxetine, fluoxetine, and bupropion — substantially reduce conversion to hydromorphone (83% reduction with paroxetine), decreasing analgesic efficacy while leaving sedation and respiratory depression unchanged.[17]
Neuroscience[edit]
Reward and reinforcement
Hydrocodone activates the brain's mesolimbic pathway — the central circuit underlying opioid reward. μ-Opioid receptor activation in the ventral tegmental area releases inhibition on dopamine neurons, increasing dopamine release in the nucleus accumbens.[14] This dopamine surge drives the euphoria and reinforcement characteristic of opioid use.
The reward signal has two dissociable components: wanting (dopamine-driven motivation to seek the drug) and liking (opioid-driven subjective pleasure). With chronic use, wanting sensitizes while liking diminishes through tolerance — producing the clinical pattern of escalating drug-seeking with diminishing subjective reward. This dissociation explains why individuals with opioid use disorder continue compulsive use despite reporting less pleasure from each dose.
Pain modulation and tolerance
Hydrocodone's analgesic effect engages a top-down pain suppression system: μ-opioid receptor activation in the periaqueductal gray triggers a relay through the brainstem to the spinal cord, where descending projections inhibit pain signals at the first central synapse.
Tolerance develops through a molecular cascade at the cellular level — receptor desensitization, removal of receptors from the cell surface, and compensatory upregulation of excitatory signaling pathways. When opioid use stops, these compensatory changes produce the withdrawal: the upregulated excitatory systems, no longer suppressed by the drug, drive anxiety, rapid heart rate, sweating, and gut hyperactivity through excessive norepinephrine release from the locus coeruleus.
Several questions remain unresolved. The relative contribution of hydrocodone versus its metabolite hydromorphone to reward, respiratory depression, and constipation has not been separately quantified. Whether hydrocodone exhibits biased signaling at the μ-opioid receptor — favoring one intracellular pathway over another — is uncharacterized, a gap relevant to the development of safer analgesics. The specific neural circuit changes that convert controlled pain management into compulsive drug-seeking in a subset of patients remain incompletely mapped.
Subjective Effects[edit]
The hydrocodone experience is characteristic of full μ-opioid agonists: a warm, enveloping body sensation that dissolves pain awareness and anxiety into a diffuse, heavy contentment. At low doses, the primary effect is pain suppression with mild sedation and mood elevation. At moderate doses, a pronounced euphoria emerges alongside cognitive slowing and physical relaxation. At high doses, sedation deepens toward a nodding stupor, and respiratory depression becomes clinically significant. The experience is profoundly shaped by genetic metabolizer status — individuals who convert little hydrocodone to its active metabolite may find the compound predominantly sedating with limited euphoria.
Relative to morphine, hydrocodone produces a qualitatively similar but somewhat milder subjective experience at equivalent doses, with less nausea and histamine-mediated flushing. Compared to oxycodone, it is generally described as more sedating and less stimulating, though direct controlled comparisons of subjective quality at matched doses are sparse.
Effect Grid
At 10–25 mg oral, the full opioid effect profile manifests. Clear cognitive euphoria, significant pain suppression, moderate sedation, and pronounced anxiety suppression characterize this range. A warm, enveloping body high with tactile euphoria becomes the dominant physical sensation. Thought deceleration and focus suppression are noticeable — driving and complex cognitive tasks are meaningfully impaired.
Nausea is common, especially in opioid-naive users or during dose escalation. Constipation is likely at repeated doses. Pupil constriction is clearly visible. Itching and flushing from histamine release may occur. Spontaneous body sensations — warmth radiating through the trunk and limbs — are characteristic. Respiratory depression is present but generally subclinical in healthy individuals without CNS depressant co-ingestion.
Emotional suppression and motivation suppression may become noticeable. Total duration is typically 4–8 hours. Combination products containing acetaminophen impose an independent hepatotoxicity ceiling regardless of opioid tolerance — do not exceed acetaminophen daily limits.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing suppression
Constipation · Pain suppression · Sedation · Bodily heaviness · Muscle relaxation · Physical fatigue · Tactile euphoria · Dizziness · Nausea · Spontaneous body sensations · Dry mouth · Tingling / electric sensations · Appetite suppression · Excessive sweating · Sexual arousal suppression · Headache · Heart rate perception changes · Temperature dysregulation · Vomiting · Abnormal heartbeat · Nasal congestion · Nystagmus (eye wobbles) · Watery eyes · Yawning · Involuntary body movements · Restlessness · Bodily dissociation
Bodily heaviness · Muscle relaxation · Physical fatigue · Tactile euphoria · Dizziness · Nausea · Spontaneous body sensations · Dry mouth · Tingling / electric sensations · Appetite suppression · Excessive sweating · Sexual arousal suppression · Headache · Heart rate perception changes · Vomiting · Abnormal heartbeat · Nasal congestion · Nystagmus (eye wobbles) · Watery eyes · Yawning · Involuntary body movements · Restlessness · Bodily dissociation
Thought deceleration · Analysis suppression · Focus suppression · Information processing suppression · Delusions of sobriety · Memory suppression · Motivation suppression · Confusion · Language suppression · Memory fragmentation · Thought disorganization · Cognitive dysphoria
Information processing suppression · Memory suppression · Motivation suppression · Confusion · Language suppression · Memory fragmentation · Thought disorganization · Cognitive dysphoria
Anxiety · Dysphoria · Emotional lability · Irritability
Social disconnection · Depersonalization · Derealization · Cognitive disconnection
Timeline
Initial awareness of effects — subtle warmth spreading from the core, faint mood elevation, first hints of pain attenuation. Effects may be ambiguous at this stage.
Building analgesia and sedation, warmth intensifying through the body. Nausea may emerge, particularly in opioid-naive users. Anxiolytic effects become noticeable.
Maximum euphoria, analgesia, sedation, and anxiety suppression. Respiratory depression is greatest during this phase. Pupil constriction, constipation, and body high are fully expressed.
Gradual decline in euphoria and analgesia. Sedation may persist longer than other effects. Cognitive impairment and motor control impairment linger as subjective warmth fades.
Residual sedation, mild cognitive impairment, possible constipation persisting. Some residual mood elevation or contentment.
⚠ Do not drive or operate heavy machinery for at least 6 hours after last dose, or longer if sedation persists.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- morphine · oxycodone · heroin
Toxicity
Acute toxicity
The primary lethal mechanism of hydrocodone is progressive respiratory depression — dose-dependent suppression of breathing drive at the brainstem, progressing to stopped breathing and death from oxygen deprivation.[20] Autopsy findings in opioid-related deaths characteristically include fluid-filled lungs.[20] Pre-existing respiratory conditions, obesity, sleep apnea, or concurrent use of other depressants dramatically lower the lethal threshold.
No specific lethal dose has been established in humans. In opioid-naïve individuals, doses in the heavy range (40+ mg oral) may be fatal, particularly with depressant co-ingestion.safety citation needed Tolerance shifts the lethal threshold upward, but tolerance to respiratory depression develops incompletely and unpredictably.
Acetaminophen hepatotoxicity
Most prescribed hydrocodone formulations pair it with acetaminophen. Liver failure in hydrocodone overdose typically arises from the acetaminophen component, not hydrocodone itself. Acetaminophen accounts for more than 50% of U.S. Overdose-related acute liver failure.citation needed The FDA mandated in 2014 that combination products contain no more than 325 mg acetaminophen per dosage unit. N-acetylcysteine is the specific antidote for acetaminophen-induced liver damage but does not address opioid-mediated effects.
Epidemiological context
Opioid use disorder caused 53,774 U.S. deaths in 2024 and affected 3.7% of adults.[21] Opioid analgesic poisoning deaths — driven substantially by hydrocodone prescribing — exceeded heroin and cocaine deaths combined by 2002[6] and subsequently surpassed deaths from suicide and motor vehicle crashes.[2]
Psychological risks
Hydrocodone produces dose-dependent cognitive impairment, including slowed reaction time, decision impairment, and memory disruption. The primary psychological risks include:
- Compulsive redosing — the reinforcing warmth and anxiety relief drive dose escalation, particularly in individuals with untreated pain or anxiety disorders
- Cognitive impairment — thought deceleration, impaired attention, and poor judgment that persist throughout the duration of action and impair driving and work performance
- Depression and emotional flatness — chronic use reduces the brain's natural opioid and dopamine activity, producing persistent low mood during abstinence that reinforces continued use
- Emotional suppression — chronic opioid use blunts the full range of emotional experience, contributing to social withdrawal
- Confusion and delirium — particularly in elderly patients, those with liver impairment, or at high doses
Severe psychological distress is more commonly associated with withdrawal than with acute intoxication. Hydrocodone does not produce hallucinations, paranoia, or thought disorder at typical doses.
Tolerance and dependence
Tolerance develops with regular use through desensitization of μ-opioid receptors and compensatory excitatory adaptations. Tolerance develops differentially: analgesic and euphoric tolerance emerge relatively quickly, while tolerance to constipation and pupil constriction develops slowly or incompletely. Cross-tolerance occurs with all μ-opioid agonists.
Physical dependence develops with regular use beyond 1–2 weeks. The opioid withdrawal syndrome reflects rebound effect excitation when the drug is removed: anxiety, insomnia, muscle pain, nausea, vomiting, diarrhea, sweating, goosebumps, watery eyes, runny nose, yawning, and rapid heart rate. Withdrawal is intensely unpleasant but rarely life-threatening in otherwise healthy individuals — distinguishing it from alcohol and benzodiazepine withdrawal, which carry seizure and death risk.
Evidence-based treatment for opioid use disorder includes buprenorphine-naloxone (partial agonist therapy), methadone (full agonist substitution), and naltrexone (antagonist-based relapse prevention).[21]
Only approximately 44.5% of chronic non-cancer pain patients maintain stable pain levels and opioid doses over 12 months on extended-release opioids, reflecting the clinical reality of tolerance development.[22]
Drug interactions
Alcohol
Alcohol combines two dangers with hydrocodone: additive respiratory depression and accelerated drug absorption. Alcohol increases peak hydrocodone blood levels by approximately 135% and cuts the time to peak from 6 hours to 2.4 hours for extended-release formulations.[23] Even moderate alcohol concentrations increased adverse event rates from 10% to 24.1%. Alcohol-opioid combinations are a leading contributor to fatal overdose.[24]
Benzodiazepines
Benzodiazepine co-ingestion is one of the most significant risk factors for opioid overdose death. Deaths occur at lower drug concentrations than would be expected for either substance alone, indicating synergistic toxicity.[25] Benzodiazepine-related deaths increased 5-fold from 1999–2009, largely driven by opioid co-ingestion.[24]
GHB and GBL
GHB produces depressant effects through a different receptor system. Combined with hydrocodone, the result is additive or synergistic respiratory depression.[26] Naloxone does not reverse GHB-induced respiratory depression — only the opioid component responds to naloxone.
Tramadol
Tramadol combines opioid activity with effects on serotonin and norepinephrine. Co-administration with hydrocodone produces additive respiratory depression and increases seizure risk.[27]
Ketamine
Unmonitored combination of ketamine with hydrocodone produces compounded depressant effects, cardiovascular suppression, and respiratory impairment. While ketamine-opioid combinations are used in monitored medical settings, recreational-dose combinations carry serious risk.safety citation needed
Contraindications
Absolute contraindications
- Severe respiratory depression or acute/severe asthma — hydrocodone's primary lethal mechanism is respiratory depression; pre-existing respiratory compromise eliminates the margin between therapeutic and lethal effect
- Known hypersensitivity to hydrocodone — severe allergic reactions are documented with opioid administration
- Concurrent or recent MAOI use — potential for dangerous interaction; 14-day washout before opioid initiation is standard
Relative contraindications
- Head injury or elevated pressure within the skull — opioids increase cerebrospinal fluid pressure and produce sedation that confounds neurological assessment
- Liver impairment — altered enzyme activity changes the ratio of active to inactive metabolites unpredictably
- Ultra-rapid metabolizer status — excessive conversion to the active metabolite may produce disproportionate effects at standard doses[15]
- Pregnancy — neonatal opioid withdrawal syndrome is documented with in-utero opioid exposure[28]
- Concurrent benzodiazepine or depressant use — synergistic respiratory depression and elevated overdose mortality risk[25][24]
- Biliary tract disease or acute pancreatitis — opioids increase muscle tone in the bile duct, potentially worsening obstruction
- Severe kidney impairment — reduced clearance with unpredictable drug accumulation
Harm Reduction[edit]
Forms & Identification
Hydrocodone enters unregulated circulation almost exclusively as diverted pharmaceutical tablets — the same manufactured pills prescribed by physicians. The critical risk is counterfeit tablets: pressed pills designed to look identical to legitimate products but containing fentanyl or fentanyl analogs at unpredictable and potentially lethal doses. No visual inspection, taste, or smell can distinguish a counterfeit from a genuine tablet.
Fentanyl test strips can detect fentanyl contamination in a dissolved tablet sample, but a negative result does not guarantee safety — fentanyl distribution within a pressed tablet is uneven, and the tested portion may not represent the whole pill. Verification of pharmaceutical origin (sealed pharmacy packaging, intact lot numbers) remains the only reliable method of confirming tablet identity.
Guidelines
- Test any tablet of uncertain origin with fentanyl test strips before use
- Start with the lowest effective dose, particularly if tolerance status is uncertain or has changed — even days of abstinence reduce tolerance meaningfully
- Never combine with alcohol, benzodiazepines, other opioids, or sedatives
- Do not crush, break, or chew extended-release tablets — this releases the full dose at once
- Keep naloxone accessible and ensure at least one person present knows how to use it
- Do not use alone — respiratory depression can progress to death within minutes, and the person affected cannot self-rescue
- Track total acetaminophen intake from all sources if using combination products — do not exceed 3,000 mg per day
Set & Setting
Opioids reduce alertness, reaction time, and judgment. Use in isolation is the primary environmental risk factor for fatal overdose — if breathing stops, no one is present to intervene. The presence of a sober, informed companion who can recognize respiratory depression and administer naloxone is the single most effective environmental safeguard.
Avoid situations requiring coordination, driving, or decision-making. Comfortable, familiar environments with access to emergency services reduce secondary risk.
Aftercare & integration. The period following opioid use requires attention to physical recovery. Constipation is cumulative with repeated use — adequate hydration and fiber intake help manage gut function. Cognitive fog and slowed reaction time may persist for hours after subjective effects fade; avoid driving or demanding tasks during this period.
For individuals reflecting on patterns of escalating use, honest self-assessment is more valuable than rationalization. Warning signs include using more than prescribed, taking doses closer together, continuing use after the original pain has resolved, and using to manage emotional distress rather than physical pain. If these patterns are present, early intervention produces substantially better outcomes.
Recovery & Support
Opioid use disorder is a treatable medical condition. Evidence-based options include medication-assisted treatment with buprenorphine-naloxone (Suboxone) or methadone, which stabilize opioid receptors and reduce cravings without producing the cycle of intoxication and withdrawal. Naltrexone offers an antagonist-based approach for individuals who have completed detoxification.
Abrupt cessation after physical dependence has developed produces severe withdrawal. While rarely life-threatening, unmanaged withdrawal drives relapse in the majority of cases. Medically supervised tapering or medication-assisted treatment produces better long-term outcomes than unsupported abstinence.
Support resources include SAMHSA's National Helpline (1-800-662-4357), local harm reduction organizations that provide naloxone and safer use supplies, and peer support groups. Treatment works — the evidence consistently shows that medication-assisted treatment reduces overdose death, infectious disease transmission, and criminal justice involvement.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
The transition from heavy sedation to life-threatening overdose can be subtle. Red flags that demand immediate action:
- Breathing has slowed to fewer than 8 breaths per minute, become irregular, or stopped
- Lips, fingernails, or skin have turned blue or grey
- Person is unresponsive to voice or sternal rub (knuckles pressed firmly on the breastbone)
- Choking or gurgling sounds during unconsciousness
- Pinpoint pupils with any of the above
Immediate steps
- 1. Call emergency services immediately
- 2. Administer naloxone if available — intranasal (one spray in one nostril) or intramuscular injection; naloxone reverses opioid-induced respiratory depression within 2–3 minutes
- 3. If no response after 2–3 minutes, administer a second dose of naloxone
- 4. Place the person in the recovery position (on their side) to prevent choking on vomit
- 5. Perform rescue breathing if trained: one breath every 5 seconds
- 6. Do NOT leave the person alone — naloxone wears off in 30–90 minutes, and respiratory depression may return
- 7. Do NOT induce vomiting
What to tell the dispatcher
State the substance involved (opioid/hydrocodone), approximate amount and time taken, current symptoms (not breathing, unresponsive, blue lips), and whether naloxone has been given. Good Samaritan laws in most U.S. states and many other jurisdictions provide legal protection to people who call for help during an overdose.
Naloxone
Narcan (naloxone) is a life-saving opioid reversal agent available without prescription in most U.S. states. It has no effect on non-opioid substances and cannot cause harm if administered unnecessarily. Naloxone precipitates immediate withdrawal symptoms in opioid-dependent individuals — this is uncomfortable but not dangerous. Always call emergency services even after successful naloxone administration, as the reversal may wear off before the opioid clears the body.
Legal Status[edit]
Hydrocodone is among the most tightly regulated opioid analgesics worldwide. In the United States, the compound's regulatory history is defined by the 2014 rescheduling of all hydrocodone combination products from Schedule III to Schedule II — a landmark action driven by the compound's central role in the American opioid epidemic.[7] The United States accounts for approximately 99% of global hydrocodone consumption,[3] making its domestic regulatory framework disproportionately significant.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | All formulations classified as Schedule II since October 6, 2014. No refills; written or electronic prescription required; 30-day supply limits in most states[7] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the strictest classification alongside heroin, morphine, and methadonecitation needed |
| Canada | Controlled substance (narcotic) | Available under the brand name Hycodan; regulated under the Controlled Drugs and Substances Act[5] |
| Australia | Schedule 8 (controlled drug)citation needed | Classification inferred from regulatory treatment of strong opioid analgesics; primary TGA source confirmation not obtained |
| European Union | Controlled narcotic | Not commercially available in most EU member states; regulation follows UN Single Convention on Narcotic Drugscitation needed |
The global regulatory landscape reflects hydrocodone's classification as a narcotic under the UN Single Convention on Narcotic Drugs (1961), which mandates that signatory nations control its manufacture, distribution, and medical use. The compound's near-exclusive concentration in the American market means most international frameworks address hydrocodone through general opioid narcotic controls rather than substance-specific legislation.
references
- [1] ^abcChen ZR, Irvine RJ, Somogyi AA, Bochner F (1991) Mu receptor binding of some commonly used opioids and their metabolites — Life Sciences PMID:1851921
- [2] ^abcManchikanti L (2012) Opioid Epidemic in the United States — Pain Physician doi:10.36076/ppj.2012/15/es9
- [3] ^abcPergolizzi JV, Breve F, Taylor RM, LeQuang JA (2017) The Aftermath of Hydrocodone Rescheduling: Intentional and Unintended Consequences — International Journal of Anesthesiology & Research doi:10.19070/2332-2780-1600078
- [4] ^abHosseinnejad K, Yin T, Gaskins JT, Stauble ME, Wu Y, Jannetto P, Langman LL, Jortani SA (2019) Lack of Influence by CYP3A4 and CYP3A5 Genotypes on Pain Relief by Hydrocodone in Postoperative Cesarean Section Pain Management — The Journal of Applied Laboratory Medicine doi:10.1373/jalm.2018.026070
- [5]
- [6] ^abPaulozzi LJ, Budnitz DS, Xi Y (2006) Increasing deaths from opioid analgesics in the United States — Pharmacoepidemiology and Drug Safety doi:10.1002/pds.1276